These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 39103676)

  • 21. Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.
    Pfeifer M; Brammeld JS; Price S; Pilling J; Bhavsar D; Farcas A; Bateson J; Sundarrajan A; Miragaia RJ; Guan N; Arnold S; Tariq L; Grondine M; Talbot S; Guerriero ML; O'Neill DJ; Young J; Company C; Dunn S; Thorpe H; Martin MJ; Maratea K; Barrell D; Ahdesmaki M; Mettetal JT; ; Brownell J; McDermott U
    Commun Biol; 2024 Apr; 7(1):497. PubMed ID: 38658677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling.
    Noland CL; Gierke S; Schnier PD; Murray J; Sandoval WN; Sagolla M; Dey A; Hannoush RN; Fairbrother WJ; Cunningham CN
    Structure; 2016 Jan; 24(1):179-186. PubMed ID: 26724994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
    Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
    BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
    Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
    EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma.
    Benton D; Yee Chow H; Karchugina S; Chernoff J
    PLoS One; 2024; 19(7):e0305121. PubMed ID: 39083549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ROCK1 mechano-signaling dependency of human malignancies driven by TEAD/YAP activation.
    Esposito D; Pant I; Shen Y; Qiao RF; Yang X; Bai Y; Jin J; Poulikakos PI; Aaronson SA
    Nat Commun; 2022 Feb; 13(1):703. PubMed ID: 35121738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ.
    Chang L; Azzolin L; Di Biagio D; Zanconato F; Battilana G; Lucon Xiccato R; Aragona M; Giulitti S; Panciera T; Gandin A; Sigismondo G; Krijgsveld J; Fassan M; Brusatin G; Cordenonsi M; Piccolo S
    Nature; 2018 Nov; 563(7730):265-269. PubMed ID: 30401838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling.
    Ota M; Sasaki H
    Development; 2008 Dec; 135(24):4059-69. PubMed ID: 19004856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells.
    Van Sciver N; Ohashi M; Pauly NP; Bristol JA; Nelson SE; Johannsen EC; Kenney SC
    PLoS Pathog; 2021 Aug; 17(8):e1009783. PubMed ID: 34339458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of the Hippo Pathway Transcription Factor TEAD.
    Lin KC; Park HW; Guan KL
    Trends Biochem Sci; 2017 Nov; 42(11):862-872. PubMed ID: 28964625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
    Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
    J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
    Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
    Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer.
    Zhu C; Li L; Zhang Z; Bi M; Wang H; Su W; Hernandez K; Liu P; Chen J; Chen M; Huang TH; Chen L; Liu Z
    Mol Cell; 2019 Aug; 75(4):791-806.e8. PubMed ID: 31303470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. YAP/TAZ-TEAD activity promotes the malignant transformation of cervical intraepithelial neoplasia through enhancing the characteristics and Warburg effect of cancer stem cells.
    Li S; Li X; Yang YB; Wu SF
    Apoptosis; 2024 Aug; 29(7-8):1198-1210. PubMed ID: 38553612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RHOA activity in expanding blastocysts is essential to regulate HIPPO-YAP signaling and to maintain the trophectoderm-specific gene expression program in a ROCK/actin filament-independent manner.
    Marikawa Y; Alarcon VB
    Mol Hum Reprod; 2019 Feb; 25(2):43-60. PubMed ID: 30395288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting YAP in malignant pleural mesothelioma.
    Zhang WQ; Dai YY; Hsu PC; Wang H; Cheng L; Yang YL; Wang YC; Xu ZD; Liu S; Chan G; Hu B; Li H; Jablons DM; You L
    J Cell Mol Med; 2017 Nov; 21(11):2663-2676. PubMed ID: 28470935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
    Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. m
    Wu J; Yi T; Zhuo C; Wang D; Zhang M; Hu R; Wu D; Hou G; Xing Y
    J Cell Physiol; 2024 May; 239(5):e31220. PubMed ID: 38372068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
    Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
    FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.